Jul 8 |
Eli Lilly to acquire Morphic for $57 a share in cash
|
Jul 8 |
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal
|
Jul 8 |
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
|
Jul 8 |
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
|
Jul 7 |
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
|
Jul 6 |
Small, mid-size biotechs could see M&A action in H2 - PwC
|
Jul 5 |
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
|
Jul 5 |
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
|
Jul 5 |
Eli Lilly Remains an Equities Outlier
|
Jul 5 |
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
|